Ensuring compliance in AI-generated medical content requires robust human oversight, clearly defined review workflows, and adherence to the regulatory codes that govern pharmaceutical and healthcare communications. AI can accelerate drafting and research, but it cannot replace the medical, legal, and regulatory expertise required to approve content for use in a regulated industry. The questions below address the specific compliance challenges that arise when AI enters the medical communications process.
What regulations govern AI-generated content in healthcare?
AI-generated medical content is subject to the same regulatory frameworks as any other promotional or educational material produced for the pharmaceutical and healthcare sectors. In the UK, the ABPI Code of Practice sets the standard for pharmaceutical promotional content. In the US, the FDA governs prescription drug advertising and labelling. Across Europe, the EFPIA Code applies, with additional national-level requirements in individual member states.
None of these frameworks contain AI-specific provisions yet, but that absence does not create a compliance gap in the way some assume. The obligation is on the content, not the tool used to produce it. A claim that requires substantiation in a human-written document requires exactly the same substantiation when generated by an AI model. Similarly, materials that must be approved by a medical signatory before use carry that requirement regardless of how the first draft was produced.
Regulators in multiple markets are actively developing guidance on AI use in regulated industries. The European Medicines Agency and the FDA have both signalled interest in this area. Organisations working in medical communications in 2026 should treat current codes as the baseline while monitoring for emerging AI-specific guidance that will almost certainly follow.
How does AI introduce compliance risk in medical writing?
AI introduces compliance risk in medical writing primarily through hallucination, outdated training data, and the absence of clinical judgement. A language model can produce confident, fluent text that contains factual errors, misattributed references, or clinical claims unsupported by the cited evidence. In a regulated environment, any one of these failures can constitute a breach of the applicable code.
The risks cluster around several specific vulnerabilities:
- Fabricated references: AI models frequently generate plausible-sounding citations that do not exist or that do not support the claim being made. Every reference in medical content must be independently verified against the source document.
- Outdated clinical information: Training data has a cutoff date. Guidelines, prescribing information, and clinical evidence evolve. AI output may reflect superseded data without signalling that it has done so.
- Tone and balance failures: Promotional materials must present a fair and balanced view of a medicine’s benefits and risks. AI models trained on broadly positive content may default to promotional language that overstates benefit or omits relevant safety information.
- Lack of indication specificity: A model may generate content that is accurate for one indication but inappropriate for another, particularly for medicines with narrow or complex licensing positions.
These risks do not make AI unusable in medical communications. They make unreviewed AI output unusable. The distinction matters, because the solution is process design rather than avoidance.
Who is responsible for approving AI-generated medical materials?
Responsibility for approving AI-generated medical materials sits with the same individuals who are responsible for approving any other medical content: qualified medical, legal, and regulatory signatories within the sponsoring organisation. AI does not change the approval chain. It changes only the origin of the draft that enters it.
Under the ABPI Code and equivalent frameworks, pharmaceutical companies bear ultimate responsibility for all materials produced on their behalf, including those created by agencies using AI tools. If an agency uses an AI model in the production process, the sponsoring company’s medical, legal, and regulatory review must still be completed before the material is used or distributed.
Internally, responsibility for managing AI use in a compliant way typically sits with the medical affairs or regulatory affairs function, often in collaboration with the legal team. Agencies working in medical communications should have clear contractual and procedural agreements with clients that define where AI has been used in the production of any given deliverable, so that reviewers can apply appropriate scrutiny to the output.
What review process should AI medical content go through?
AI-generated medical content should go through the same medical, legal, and regulatory review process as any other content, with additional verification steps applied specifically to address the risks that AI introduces. The review should not be lighter because AI was faster to produce the draft. In some respects, it should be more rigorous.
A structured review process for AI-assisted medical content typically includes the following stages:
- Medical writer review: A qualified medical writer reviews the AI output for clinical accuracy, appropriate use of language, and alignment with the approved label before the document enters formal review.
- Reference verification: Every claim and citation is checked against the primary source. This step is non-negotiable given the hallucination risk inherent in current AI models.
- Promotional versus non-promotional classification: The material is assessed to confirm whether it is promotional or non-promotional in nature, as this determines which review pathway and approval requirements apply.
- MLR review: The document goes through the standard medical, legal, and regulatory review with full documentation of changes and approvals.
- Signatory sign-off: A qualified signatory approves the final version before use, as required under the applicable code.
Some organisations are beginning to develop AI-specific addenda to their standard operating procedures, defining how AI tools may be used in content production, what disclosure is required internally, and how AI-generated sections should be flagged for reviewers. This is a sound approach and likely to become standard practice as AI use becomes more widespread.
Which AI tools are considered acceptable for pharma content creation?
No AI tool has been formally approved or endorsed by regulators for use in pharmaceutical content creation. Acceptability is therefore determined by how a tool is used and governed, not by which tool is selected. That said, there are meaningful differences between tools that affect their suitability in a regulated context.
General-purpose consumer AI tools present the highest risk because they may process and retain data entered by the user, raising concerns about the confidentiality of unpublished clinical data, proprietary information, and personal data. Using a consumer AI tool to draft content containing confidential trial data or patient information may breach data protection obligations and contractual confidentiality agreements.
Enterprise-grade AI tools with data processing agreements, private deployment options, and clear data retention policies are more appropriate for regulated environments. Several technology companies have developed AI writing tools specifically for the life sciences sector, with built-in reference checking, audit trails, and compliance-oriented workflows. These reduce some of the risk inherent in general-purpose models, though they do not eliminate the need for human review.
Organisations should evaluate any AI tool against three criteria: data security and confidentiality, the ability to audit what the tool produced and how, and whether its use is compatible with existing contractual and regulatory obligations. Procurement decisions should involve legal, IT, and compliance stakeholders rather than being made solely by communications or marketing teams.
How should AI use be disclosed in medical communications?
AI use in medical communications should be disclosed transparently — both internally within the review and approval process and, where required or appropriate, externally in the published or distributed material. The precise requirements vary by market, channel, and material type, but the direction of travel across regulatory bodies is clearly toward greater transparency.
Internally, disclosure means documenting which elements of a deliverable were AI-generated or AI-assisted, so that reviewers understand the provenance of the content they are approving. This is not simply good practice; it enables reviewers to apply the appropriate level of scrutiny to AI-generated sections and creates an audit trail that demonstrates due diligence if the material is later challenged.
Externally, some journals and congress organisers already require authors to declare AI use in submitted materials. The International Committee of Medical Journal Editors (ICMJE) has stated that AI tools cannot be listed as authors and that their use must be disclosed in the methods or acknowledgements section. For promotional and educational materials aimed at healthcare professionals, formal external disclosure requirements are still emerging, but organisations that adopt a policy of proactive transparency are better positioned as regulatory expectations develop.
A practical disclosure approach distinguishes between AI-assisted drafting — where a human writer used AI as a productivity tool and then substantially revised the output — and AI-generated content, where the AI produced the substantive text with lighter human editing. These represent different levels of AI involvement and may warrant different disclosure language.
How Wizzard approaches AI compliance in medical communications
We work at the intersection of scientific rigour and creative ambition, which means accuracy, compliance, and responsible process are central to how we produce medical communications — not an afterthought. When AI tools are part of the production process, we use them within a framework that preserves the integrity of the work and the accountability of the people behind it.
- Medical writers and strategists with deep sector experience lead all content development, with AI used to support rather than replace expert judgement
- Reference verification and clinical accuracy checks are built into the workflow, not left to the review stage
- Content is developed within client governance structures and applicable industry codes, including ABPI and equivalent frameworks in other markets
- We maintain transparency about process throughout, so that client medical, legal, and regulatory teams can review with full context
If you are working through how to integrate AI responsibly into your medical communications programme, or if you need a communications partner who understands both the science and the regulatory environment, speak to the Wizzard team about how we can help.